Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dinoprostone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 known ✓ | P35408 | 5/20 | 1.00 |
| ▸ | PTGER2 known ✓ | P43116 | 4/20 | 1.00 |
| ▸ | PTGER3 known ✓ | P43115 | 4/20 | 1.00 |
| ▸ | PTGER1 known ✓ | P34995 | 3/20 | 1.00 |
| ▸ | PTGIR | P43119 | 6/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 1.00 |
| ▸ | PTGFR | P43088 | 3/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 2/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | ESR1 | P03372 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.73 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dinoprostone SCHEMBL24340817 | 1.00 | PTGIR (1.00) | PTGIRPTGER4PTGER2PTGER3TSHR | |
| Dinoprostone SCHEMBL23909398 | 1.00 | PTGIR (1.00) | PTGIRPTGER4PTGER2PTGER3TSHR | |
| Dinoprostone SCHEMBL23353214 | 1.00 | PTGIR (1.00) | PTGIRPTGER4PTGER2PTGER3TSHR | |
| Dinoprostone SCHEMBL23352922 | 1.00 | PTGIR (1.00) | PTGIRPTGER4PTGER2PTGER3TSHR | |
| Dinoprostone SCHEMBL24223591 | 1.00 | PTGIR (1.00) | PTGIRPTGER4PTGER2PTGER3TSHR | |
| Dinoprostone SCHEMBL24727254 | 1.00 | PTGIR (1.00) | PTGIRPTGER4PTGER2PTGER3TSHR | |
| Dinoprostone SCHEMBL23352819 | 1.00 | PTGIR (1.00) | PTGIRPTGER4PTGER2PTGER3TSHR | |
| Dinoprostone SCHEMBL23352791 | 1.00 | PTGIR (1.00) | PTGIRPTGER4PTGER2PTGER3TSHR | |
| Dinoprostone SCHEMBL23352988 | 1.00 | PTGIR (1.00) | PTGIRPTGER4PTGER2PTGER3TSHR | |
| Dinoprostone SCHEMBL21374367 | 1.00 | PTGIR (1.00) | PTGIRPTGER4PTGER2PTGER3TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220401487-A1 | COMPOSITIONS AND METHODS FOR IMMUNE CELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES | FATE THERAPEUTICS, INC. | 2022-12-22 | — | — | US | claimed |
| US-11413309-B2 | Compositions and methods for immune cell modulation in adoptive immunotherapies | FATE THERAPEUTICS, INC. (US) | 2022-08-16 | — | — | US | claimed |
| US-20260144801-A1 | COMPOSITIONS AND METHODS FOR PREVENTING OR TREATING MUSCLE CONDITIONS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2026-05-28 | — | — | US | disclosed |
| EP-4706758-A2 | METHODS FOR INHIBITING PHOSPHATE TRANSPORT | Ardelyx, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20260022403-A1 | VCN ENHANCER COMPOSITIONS AND METHODS OF USING THE SAME | BLUEBIRD BIO INC (US) | 2026-01-22 | — | — | US | disclosed |
| US-20250333702-A1 | CELLS WITH INCREASED IMMUNO-REGULATORY PROPERTIES AND METHODS FOR THEIR USE AND MANUFACTURE | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-10-30 | — | — | US | disclosed |
| US-12419870-B2 | Compositions and methods for immune cell modulation in adoptive immunotherapies | FATE THERAPEUTICS, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250290097-A1 | COMPOSITIONS AND METHODS FOR MODIFYING EUKARYOTIC CELLS | ORCHARD THERAPEUTICS (EUROPE) LIMITED (GB) | 2025-09-18 | — | — | US | disclosed |
| US-20250215396-A1 | COMPOSITIONS AND METHODS FOR IMMUNE CELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES | FATE THERAPEUTICS, INC. | 2025-07-03 | — | — | US | disclosed |
| US-20250134927-A1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING AUTOIMMUNE DISEASES | ORCHARD THERAPEUTICS EUROPE LTD (GB) | 2025-05-01 | — | — | US | disclosed |
| US-12281329-B2 | Compositions and methods for immune cell modulation in adoptive immunotherapies | FATE THERAPEUTICS, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| US-11326183-B2 | VCN enhancer compositions and methods of using the same | BLUEBIRD BIO, INC. (US) | 2022-05-10 | — | — | US | disclosed |
| CN-114450412-A | Compositions and methods for modifying eukaryotic cells | 奥查德疗法(欧洲)有限公司 | 2022-05-06 | — | — | CN | disclosed |
| US-20220118021-A1 | ENHANCED STEM CELL COMPOSITION | FATE THERAPEUTICS INC (US) | 2022-04-21 | — | — | US | disclosed |
| EP-3972599-A1 | COMBINATION FOR LOWERING SERUM PHOSPHATE IN A PATIENT | Ardelyx, Inc. (US) | 2022-03-30 | — | — | EP | disclosed |
| EP-3656848-B1 | COMPOUNDS FOR IMPROVED VIRAL TRANSDUCTION | BLUEBIRD BIO INC (US) | 2022-03-16 | — | — | EP | disclosed |
| US-11261441-B2 | Vectors and compositions for treating hemoglobinopathies | BLUEBIRD BIO, INC. (US) | 2022-03-01 | — | — | US | disclosed |
| US-20220054553-A1 | METHODS OF TREATING ISCHEMIA | FATE THERAPEUTICS INC (US) | 2022-02-24 | — | — | US | disclosed |
| WO-2022036179-A2 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HEREDITARY ANGIOEDEMA | ORCHARD THERAPEUTICS (EUROPE) LIMITED (GB) | 2022-02-17 | — | — | WO | disclosed |
| US-20210139435-A1 | PROSTAGLANDIN ANALOGS AND USES THEREOF | Lifex Biolabs, Inc. | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022403-A1 | VCN ENHANCER COMPOSITIONS AND METHODS OF USING THE SAME | PTGES2, POLN, HPGDS | PTGER4 18/4885PTGER2 5/4885PTGER3 15/4885 |
| US-20210139435-A1 | PROSTAGLANDIN ANALOGS AND USES THEREOF | PTGDR, NR3C1, PTGIR | PTGER4 20/4885PTGER2 18/4885PTGER3 23/4885 |
| US-20250134927-A1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING AUTOIMMUNE DISEASES | CD4, CD74, HLA-DRB1 | PTGER4 2473/4885PTGER2 1841/4885PTGER3 1321/4885 |
| US-20250290097-A1 | COMPOSITIONS AND METHODS FOR MODIFYING EUKARYOTIC CELLS | PHAX, CD44, HCLS1 | PTGER4 4195/4885PTGER2 3190/4885PTGER3 2652/4885 |
| US-20260144801-A1 | COMPOSITIONS AND METHODS FOR PREVENTING OR TREATING MUSCLE CONDITIONS | CPT1B, HPGD, PTGES | PTGER4 136/4885PTGER2 34/4885PTGER3 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.